Axsome Therapeutics Q2 2026 Earnings Call Summary

1Key Financial Results and Metrics

Net Product Revenue: $218 million, a 46% increase year-over-year from $150 million in Q2 2025.

AUVELITY Revenue: $180.3 million, up 51% year-over-year and 18% quarter-over-quarter.

SUNOSI Revenue: $35.8 million, representing a 20% year-over-year growth.

SYMBRAVO Revenue: $2.3 million, launched in June 2025, showing initial sales growth.

Net Loss: $51.3 million ($0.99 per share), slightly higher than a net loss of $48 million ($0.97 per share) in Q2 2025.

Cash Position: Approximately $320 million in cash and cash equivalents, down from $323 million at the end of 2025.

2Strategic Updates and Business Highlights

Commercial Growth: Strong performance from AUVELITY and SUNOSI, with AUVELITY's expansion into Alzheimer's disease agitation showing promising early metrics.

Sales Force Expansion: Completed expansion of the AUVELITY sales force, contributing to a 126% increase in new-to-brand prescriptions for patients aged 65+ in the first 8 weeks post-launch.

Pipeline Development: Advancements in a broad neuroscience pipeline with six product candidates targeting ten serious conditions. Expected to file an average of one new NDA each year through 2030.

Regulatory Progress: FDA accepted NDA for AXS-12 for cataplexy in narcolepsy, with a target action date of May 1, 2027.

3Forward Guidance and Outlook

Growth Expectations: Anticipation of continued strong growth across the commercial portfolio, particularly for AUVELITY and SUNOSI.

Cost Management: Expectation of operating leverage with SG&A expenses plateauing and R&D expenses increasing due to ongoing clinical trials.

Market Access: Improved payer coverage for AUVELITY and SYMBRAVO, with AUVELITY achieving approximately 89% coverage of total lives.

4Bad News, Challenges, or Points of Concern

Net Loss: Continued net losses raise concerns about profitability and cash burn, although cash position is deemed sufficient to fund operations into cash flow positivity.

SYMBRAVO Performance: Experienced a decline in net sales from Q1 2026 due to prior period adjustments and increased utilization of the patient service program.

Market Competition: The recent approval of a new orexin receptor agonist for narcolepsy could introduce competitive pressures for AXS-12.

5Notable Q&A Insights

Alzheimer's Agitation Launch: Early feedback from prescribers is positive, indicating AUVELITY's effectiveness in reducing agitation symptoms. However, detailed data on long-term care settings and specific usage patterns is still being gathered.

Sampling Strategy: Free samples are being used to encourage trial among patients, particularly in community settings, although specific metrics on sampling proportions were not disclosed.

Market Dynamics: Prescriber feedback indicates a need for education regarding treatment options in Alzheimer's agitation, with a focus on earlier intervention.

Future DTC Campaigns: Plans for direct-to-consumer advertising are under evaluation, with current efforts focused on care partners. Overall, Axsome Therapeutics reported a strong quarter with significant revenue growth and promising pipeline developments, while also navigating challenges related to net losses and competitive pressures. The company remains optimistic about its growth trajectory and market positioning.